targacept news latest

(TRGT) News Headlines - NASDAQ.com

★ ★ ★ ☆ ☆

(TRGT) News – Find the latest company news headlines for and all the companies you research at NASDAQ.com. ... Targacept's Diabetic Gastroparesis Drug Fails to Impress - Analyst Blog.

(TRGT) News Headlines - NASDAQ.com

Targacept Inc - NASDAQ:TRGT - Stock Quote & News - TheStreet

★ ★ ★ ★ ☆

View detailed financial information, real-time news, videos, quotes and analysis on Targacept Inc (NASDAQ:TRGT). Explore commentary on Targacept Inc and hear what the experts at TheStreet are ...

Targacept Inc - NASDAQ:TRGT - Stock Quote & News - TheStreet

Targacept - news.yahoo.com

★ ★ ☆ ☆ ☆

10/7/2010 · Targacept (NMS:TRGT) , a drug developer, said its experimental drug to treat attention deficit hyperactivity disorder in adults failed a phase 2 clinical trial because it didn't improve symptoms vs. a placebo. Targacept doesn't expect AstraZeneca (NYSE:AZN - News), which licensed the drug in

Targacept - news.yahoo.com

Targacept: What's Left After Latest TC-5214 Disappointment ...

★ ★ ★ ★ ☆

12/20/2011 · Today AstraZeneca (NYSE:AZN) and Targacept (TRGT) announced the results from their second of four Phase 3 trials for TC-5214, a depression drug. The …

Targacept: What's Left After Latest TC-5214 Disappointment ...

Targacept Stock Quote. TRGT - Stock Price, News, Charts ...

★ ★ ☆ ☆ ☆

Targacept stock quote and TRGT charts. Latest stock price today and the US's most active stock market forums. Targacept (TRGT) stock price, charts, trades & the US's most popular discussion forums. ... Targacept Stock Price - TRGT . Follow TRGT. Best deals to access real time data! ... Targacept News. Latest TRGT Messages.

Targacept Stock Quote. TRGT - Stock Price, News, Charts ...

Targacept Archives - MedCity News

★ ★ ☆ ☆ ☆

Get the latest industry news first when you subscribe to our daily newsletter. We will never sell or share your information without your consent. ... MedCity News: StartUPDATES.

Targacept Archives - MedCity News

Targacept News - Pharmalot - WSJ

★ ★ ☆ ☆ ☆

Targacept - The latest news about Targacept from the WSJ Pharmalot Blog. The Business of Pharmaceuticals

Targacept News - Pharmalot - WSJ

TRGT Stock | TARGACEPT Stock Price Today | Markets Insider

★ ★ ★ ★ ★

TRGT: Get the latest Targacept stock price and detailed information including TRGT news, historical charts and realtime prices.

TRGT Stock | TARGACEPT Stock Price Today | Markets Insider

Targacept sale to Catalyst is complete | Business ...

★ ★ ★ ★ ☆

Targacept Inc.’s 15-year run as an independent company ended Thursday much as it began — tying its future to the hope of a biopharmaceutical drug breakthrough. The Winston-Salem company has ...

Targacept sale to Catalyst is complete | Business ...

CBIO Analysis & News - Catalyst Biosciences, Inc ...

★ ★ ☆ ☆ ☆

Latest Breaking news and Headlines on Catalyst Biosciences, Inc. (CBIO) stock from Seeking Alpha. Read the news as it happens! ... Targacept Might Be One Company To Stay Away From - For Now.

CBIO Analysis & News - Catalyst Biosciences, Inc ...

Targacept News - Venture Capital Dispatch - WSJ

★ ★ ☆ ☆ ☆

Targacept - The latest news about Targacept from the WSJ Venture Capital Dispatch Blog. An inside look from VentureWire at high-tech startups and their investors.

Targacept News - Venture Capital Dispatch - WSJ

Targacept begins phase II pain trial - Pharmaceutical ...

★ ★ ★ ★ ☆

Targacept has initiated a phase II trial of TC-2696, its product candidate for the treatment of acute post-operative pain. Subscribe to our email newsletter The proof of concept trial is designed to evaluate the analgesic effects of TC-2696 following dental surgery.

Targacept begins phase II pain trial - Pharmaceutical ...

Targacept announces a new round of job cuts | myfox8.com

★ ★ ☆ ☆ ☆

10/8/2012 · WINSTON-SALEM, N.C. (AP) - Targacept Inc. said Monday it will eliminate 26 jobs, or 38 percent of its staff positions, as it tries to cut more costs after its second significant drug failure of ...

Targacept announces a new round of job cuts | myfox8.com

Another Miss for Targacept; TC-5619 Fails in ADHD Trial ...

★ ★ ★ ★ ★

Targacept Inc.'s TC-5619 missed its endpoint in a Phase II study in inattentive-predominant attention deficit hyperactivity disorder (iADHD), the latest in a string of disappointing news for its neuronal nicotinic receptor (NNR) pipeline. The iADHD study randomized 175 patients to receive one of two ...

Another Miss for Targacept; TC-5619 Fails in ADHD Trial ...

Targacept’s latest target: digestion - Triad Business Journal

★ ★ ★ ☆ ☆

Targacept plans to launch a new clinical study of a drug it hopes may be an effective treatment for the digestive disorder gastroparesis. Gastroparesis is a chronic condition that slows the ...

Targacept’s latest target: digestion - Triad Business Journal

Troubled Targacept whacks laboratory ops in latest ...

★ ★ ☆ ☆ ☆

10/8/2012 · Troubled Targacept whacks laboratory ops in latest restructuring. ... the spring that it would lay off 65 staffers and its CEO departed soon afterwards.The bad …

Troubled Targacept whacks laboratory ops in latest ...

Analysis of Targacept: Seth Klarman's New Purchase ...

★ ★ ★ ★ ☆

12/16/2011 · In summary, I believe Targacept presents 50% or more upside with minimal downside because of the quality of the firm's balance sheet, the potential revenue from TC-5214, the further development of the remainder of their product pipeline, and the high percentage of shares held by committed long-term investors.

Analysis of Targacept: Seth Klarman's New Purchase ...

Targacept Launches IPO, But at Less Than Hoped for Amount

★ ★ ☆ ☆ ☆

Get the latest news › ... Targacept Launches IPO, But at Less Than Hoped for Amount. Posted April 13, 2006 WINSTON-SALEM, N.C. — Targacept , the biopharmaceutical spinoff from RJ Reynolds ...

Targacept Launches IPO, But at Less Than Hoped for Amount

Company news: AstraZeneca, Targacept - MM&M - Medical ...

★ ★ ★ ★ ☆

10/9/2012 · Ardelyx has licensed its line of NHE3 inhibitors to AstraZeneca for $35 million up front and an additional $237.5 million in milestone fees. The agreement includes the Phase II drug RDX5791, which Ardelyx has put through testing for irritable bowel syndrome. The company said in a statement that the ...

Company news: AstraZeneca, Targacept - MM&M - Medical ...

Company News: AstraZeneca and Targacept - MM&M

★ ★ ★ ☆ ☆

12/4/2009 · AstraZeneca has tapped former CNS drug-development partner Targacept again, this time agreeing to pay up to $1.2 billion to in-license phase-II depression drug TC-5214. As part of the deal, AZ’s largest of the year in terms of upfront payments, it will pay Targacept an upfront of $200 million upon effectiveness and up to an additional $540 million if certain development, regulatory and first ...

Company News: AstraZeneca and Targacept - MM&M

Targacept compounds show long-lasting improvement in ...

★ ★ ★ ★ ★

6/30/2005 · Winston-Salem, NC, June 30, 2005 - In a review of research to be published in the July issue of Trends In Pharmacological Sciences, Targacept compounds were …

Targacept compounds show long-lasting improvement in ...

Targacept Fumbles the Bad News on Alzheimer’s | In the ...

★ ★ ☆ ☆ ☆

7/14/2014 · Targacept has been working on some very hard therapeutic areas over the years, and coming up dry – dramatically so.They may have just done it again. They’ve been testing TC-1734 in Alzheimer’s over the last year or so, a partial agonist at nicotinergic receptors. That was a long-shot mechanism to start with, although to be sure, every Alzheimer’s drug is a long-shot mechanism.

Targacept Fumbles the Bad News on Alzheimer’s | In the ...

Targacept, AstraZeneca to end drug research and licensing ...

★ ★ ★ ★ ★

10/9/2014 · Winston-Salem-based Targacept and pharmaceutical giant AstraZeneca have ended a nearly 10-year-old research and licensing agreement on a drug that had been designed to …

Targacept, AstraZeneca to end drug research and licensing ...

Targacept and Catalyst Biosciences Agree to Merge

★ ★ ★ ☆ ☆

3/6/2015 · Targacept and Catalyst Biosciences entered into a definitive agreement to merge the two companies into a new company that will be named Catalyst …

Targacept and Catalyst Biosciences Agree to Merge

Targacept Announces Presentations at Upcoming Conferences

★ ★ ☆ ☆ ☆

11/14/2013 · The presentations will be webcast and accessible from the Investor Relations page of Targacept's website, www.targacept.com. To ensure a timely connection to the webcasts, it is recommended that ...

Targacept Announces Presentations at Upcoming Conferences

Targacept’s Antidepressant Fails, And How | In the Pipeline

★ ★ ☆ ☆ ☆

11/8/2011 · Bad news yesterday from Targacept, a small company that’s been developing an antidepressant with AstraZeneca. TC-5214 (the S enantiomer of the nicotinic ligand mecamylamine) missed its endpoints in a trial of 295 patients in Europe who had not responded to …

Targacept’s Antidepressant Fails, And How | In the Pipeline

Topix Forums Sunset

★ ★ ★ ★ ★

For over a decade Topix has proudly served up your town's latest news and hottest takes. In that time a lot has changed. We have grown to be one of the internet's largest entertainment sources.

Topix Forums Sunset

10-K: TARGACEPT INC - MarketWatch

★ ★ ★ ★ ☆

3/14/2014 · (EDGAR Online via COMTEX) -- Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations. You should read the …

10-K: TARGACEPT INC - MarketWatch

Targacept Receives $2 Million Grant for New Drug Research ...

★ ★ ★ ★ ★

WINSTON-Targacept has received a $2 million grant to assist in the development of computer simulation software for use in new drug development. The grant, which will be provided over three years ...

Targacept Receives $2 Million Grant for New Drug Research ...

Targacept Expands Office and Lab Space | GEN - Genetic ...

★ ★ ★ ★ ☆

2/1/2007 · Targacept decided to expand its office and laboratory space in the Piedmont Triad Research Park (PTRP) in Winston-Salem, NC. ... Home News Targacept Expands Office and Lab Space. ...

Targacept Expands Office and Lab Space | GEN - Genetic ...

Targacept ends Alzheimer's drug trial after mid-stage failure

★ ★ ★ ★ ★

7/14/2014 · The latest failure marks another setback to Targacept's already thinning pipeline. In September, the company discontinued the development of its schizophrenia drug, TC-5619 after it failed a mid-stage study. (Reporting By Amrutha Penumudi; Editing by Don Sebastian)

Targacept ends Alzheimer's drug trial after mid-stage failure

Targacept Inc. whose founder & CEO has ties to Wake Forest ...

★ ★ ★ ☆ ☆

7/22/2009 · Targacept Inc., whose founder and CEO has ties to Wake Forest University and the Schools of Business, is celebrating positive results from a Phase 2b clinical trial involving a drug to treat depression. On Wednesday, July 15, the Winston-Salem-based, clinical-stage biopharmaceutical company saw its stock price rise 136.9 percent, to $7.25 per ...

Targacept Inc. whose founder & CEO has ties to Wake Forest ...

Targacept lands potential $1.2 billion deal with ...

★ ★ ★ ☆ ☆

12/3/2009 · Get the latest news alerts: at Twitter. ... with a deal announced early Thursday that could be worth more than a whopping $1 billion.Drug giant AstraZeneca and Targacept announced their ...

Targacept lands potential $1.2 billion deal with ...

Targacept, Inc. (TRGT) President and Chief Executive ...

★ ★ ☆ ☆ ☆

12/2/2010 · Targacept, Inc. (TRGT) will visit the NASDAQ MarketSite in New York City's Times Square. In honor of the occasion, J. Donald deBethizy, Ph.D., President and Chief Executive Officer of …

Targacept, Inc. (TRGT) President and Chief Executive ...

TRGT Share Price Target - Targacept, Inc. NASDAQ USA Chart ...

★ ★ ★ ★ ☆

TRGT Latest News Your Comments and Response on Targacept, Inc. ... Targacept, Inc. is a biopharmaceutical company. The Company is engaged in the design, discovery and development of NNR Therapeutics for the treatment of diseases and disorders of the nervous system. The Company's NNR Therapeutics target neuronal nicotinic receptors (NNRs).

TRGT Share Price Target - Targacept, Inc. NASDAQ USA Chart ...

Troubled Targacept whacks laboratory ops in latest ...

★ ★ ★ ★ ★

Targacept said back in the spring that it would lay off 65 staffers and its CEO departed soon afterwards.The bad news just keeps coming for Targacept. Just a few weeks ago the developer reported that its mid-stage study for an ADHD drug failed. And Targacept Chairman Mark Skaletsky wasted no time in raising the issue of fresh cuts.

Troubled Targacept whacks laboratory ops in latest ...

Targacept Inc - NASDAQ:TRGT - Stock Quote & News - TheStreet

★ ★ ★ ☆ ☆

View detailed financial information, real-time news, videos, quotes and analysis on Targacept Inc (NASDAQ:TRGT). Explore commentary on Targacept Inc and hear what the experts at TheStreet are ...

Targacept Inc - NASDAQ:TRGT - Stock Quote & News - TheStreet

Targacept Inc. - News, Articles etc. - European ...

★ ★ ☆ ☆ ☆

AstraZeneca and Targacept initiate phase IIB clinical trial of TC-5214 as a switch monotherapy treatment for major depressive disorder. 7 February 2011 | By AstraZeneca This study is in addition to the companies’ Phase III RENAISSANCE programme for TC-5214...

Targacept Inc. - News, Articles etc. - European ...
how-do-i-apply-for-incapacity-benefit.html,how-does-diversity-benefit-society.html,how-to-apply-for-child-benefit-uk-online.html,how-to-calculate-defined-benefit-pension-plan.html,how-to-claim-sss-burial-benefit.html